Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169

1.

Structure-based design, synthesis and validation of CD4-mimetic small molecule inhibitors of HIV-1 entry: conversion of a viral entry agonist to an antagonist.

Courter JR, Madani N, Sodroski J, Schön A, Freire E, Kwong PD, Hendrickson WA, Chaiken IM, LaLonde JM, Smith AB 3rd.

Acc Chem Res. 2014 Apr 15;47(4):1228-37. doi: 10.1021/ar4002735. Review.

2.

Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120.

Schön A, Madani N, Klein JC, Hubicki A, Ng D, Yang X, Smith AB 3rd, Sodroski J, Freire E.

Biochemistry. 2006 Sep 12;45(36):10973-80.

3.

Structure-based design, synthesis, and characterization of dual hotspot small-molecule HIV-1 entry inhibitors.

LaLonde JM, Kwon YD, Jones DM, Sun AW, Courter JR, Soeta T, Kobayashi T, Princiotto AM, Wu X, Schön A, Freire E, Kwong PD, Mascola JR, Sodroski J, Madani N, Smith AB 3rd.

J Med Chem. 2012 May 10;55(9):4382-96. doi: 10.1021/jm300265j.

4.

Envelope conformational changes induced by human immunodeficiency virus type 1 attachment inhibitors prevent CD4 binding and downstream entry events.

Ho HT, Fan L, Nowicka-Sans B, McAuliffe B, Li CB, Yamanaka G, Zhou N, Fang H, Dicker I, Dalterio R, Gong YF, Wang T, Yin Z, Ueda Y, Matiskella J, Kadow J, Clapham P, Robinson J, Colonno R, Lin PF.

J Virol. 2006 Apr;80(8):4017-25.

5.
6.

Binding mode characterization of NBD series CD4-mimetic HIV-1 entry inhibitors by X-ray structure and resistance study.

Curreli F, Kwon YD, Zhang H, Yang Y, Scacalossi D, Kwong PD, Debnath AK.

Antimicrob Agents Chemother. 2014 Sep;58(9):5478-91. doi: 10.1128/AAC.03339-14.

7.

Synthesis, antiviral activity and resistance of a novel small molecule HIV-1 entry inhibitor.

Curreli F, Haque K, Xie L, Qiu Q, Xu J, Yong W, Tong X, Debnath AK.

Bioorg Med Chem. 2015 Dec 15;23(24):7618-28. doi: 10.1016/j.bmc.2015.11.006.

8.

Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state.

Haim H, Si Z, Madani N, Wang L, Courter JR, Princiotto A, Kassa A, DeGrace M, McGee-Estrada K, Mefford M, Gabuzda D, Smith AB 3rd, Sodroski J.

PLoS Pathog. 2009 Apr;5(4):e1000360. doi: 10.1371/journal.ppat.1000360.

9.

Peptides from second extracellular loop of C-C chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1.

Dogo-Isonagie C, Lam S, Gustchina E, Acharya P, Yang Y, Shahzad-ul-Hussan S, Clore GM, Kwong PD, Bewley CA.

J Biol Chem. 2012 Apr 27;287(18):15076-86. doi: 10.1074/jbc.M111.332361.

10.

Discovery of small-molecule human immunodeficiency virus type 1 entry inhibitors that target the gp120-binding domain of CD4.

Yang QE, Stephen AG, Adelsberger JW, Roberts PE, Zhu W, Currens MJ, Feng Y, Crise BJ, Gorelick RJ, Rein AR, Fisher RJ, Shoemaker RH, Sei S.

J Virol. 2005 May;79(10):6122-33.

11.

Naturally occurring variability in the envelope glycoprotein of HIV-1 and development of cell entry inhibitors.

Brower ET, Schön A, Freire E.

Biochemistry. 2010 Mar 23;49(11):2359-67. doi: 10.1021/bi1000933.

12.

Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4.

Zhao Q, Ma L, Jiang S, Lu H, Liu S, He Y, Strick N, Neamati N, Debnath AK.

Virology. 2005 Sep 1;339(2):213-25.

14.

Design, synthesis and biological evaluation of small molecule inhibitors of CD4-gp120 binding based on virtual screening.

Lalonde JM, Elban MA, Courter JR, Sugawara A, Soeta T, Madani N, Princiotto AM, Kwon YD, Kwong PD, Schön A, Freire E, Sodroski J, Smith AB 3rd.

Bioorg Med Chem. 2011 Jan 1;19(1):91-101. doi: 10.1016/j.bmc.2010.11.049.

15.

A peptidomimetic HIV-entry inhibitor directed against the CD4 binding site of the viral glycoprotein gp120.

Neffe AT, Meyer B.

Angew Chem Int Ed Engl. 2004 May 24;43(22):2937-40. No abstract available.

PMID:
15170309
16.

Discovery of small molecular inhibitors targeting HIV-1 gp120-CD4 interaction drived from BMS-378806.

Liu T, Huang B, Zhan P, De Clercq E, Liu X.

Eur J Med Chem. 2014 Oct 30;86:481-90. doi: 10.1016/j.ejmech.2014.09.012. Review.

PMID:
25203778
17.

The active core in a triazole peptide dual-site antagonist of HIV-1 gp120.

Umashankara M, McFadden K, Zentner I, Schön A, Rajagopal S, Tuzer F, Kuriakose SA, Contarino M, Lalonde J, Freire E, Chaiken I.

ChemMedChem. 2010 Nov 8;5(11):1871-9. doi: 10.1002/cmdc.201000222.

18.

Small-Molecule CD4 Mimics Containing Mono-cyclohexyl Moieties as HIV Entry Inhibitors.

Ohashi N, Harada S, Mizuguchi T, Irahara Y, Yamada Y, Kotani M, Nomura W, Matsushita S, Yoshimura K, Tamamura H.

ChemMedChem. 2016 Apr 19;11(8):940-6. doi: 10.1002/cmdc.201500590.

PMID:
26891461
19.

Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41.

Lu L, Yu F, Cai L, Debnath AK, Jiang S.

Curr Top Med Chem. 2016;16(10):1074-90. Review.

Supplemental Content

Support Center